Lenalidomide in Refractory Multiple Myeloma: NCT07210047 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 15 October 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 1/2
Clinical phase
Recruiting
Recruitment status
not reported
Planned enrollment
2027-11-30
Primary-completion proxy
Executive view
NCT07210047 evaluates Lenalidomide in Refractory Multiple Myeloma. The disclosed sponsor is Hunilife Biotechnology, Inc., the design is Interventional, and the geographic footprint is Taiwan Province. The first listed primary endpoint is Myeloma responses, including sCR, CR, VGPR, PR, MR, SD, PD, clinical relapse, ORR, CBR, DoR, time to sCR, time to CR, time to VGPR, time to PR, time to MR, as assessed by the investigator according to the IMWG criteria., assessed over From enrollment to the end of treatment at 8 months.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07210047 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Refractory Multiple Myeloma landscape. Drug & Asset MCP drug_fetch was queried for Lenalidomide, while Company & Deal Intelligence MCP organization_fetch was queried for Hunilife Biotechnology, Inc..
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07210047 | Lenalidomide | Phase 1/2 / Recruiting | Hunilife Biotechnology, Inc. | Taiwan Province | Myeloma responses, including sCR, CR, VGPR, PR, MR, SD, PD, clinical relapse, ORR, CBR, DoR, time to sCR, time to CR, t… From enrollment to the end of treatment at 8 months | 2027-11-30 |
| NCT07280013 | Cemsidomide | Phase 1 / Recruiting | C4 Therapeutics, Inc. | United States | Safety and tolerability of cemsidomide in combination with elranatamab Cycle 1 approximately 28 days | 2028-12-01 |
| NCT07280793 | BCMA CAR-T Cell(Xuzhou Medical University) | Early Phase 1 / Not yet recruiting | Xuzhou Medical University | Geography not reported | Biodistribution of 68Ga-NOTA-BCMA Baseline (pre-CAR-T), and at Day 6±2, Day 11±2, Day 21±2 post-CAR-T i… | 2027-12-30 |
| NCT07270263 | Rivaroxaban | Not Applicable / Recruiting | Medical University of Gdansk | Poland | Incidence of Venous Thromboembolism (VTE) 6 months from randomization | 2026-04-30 |
| NCT07266441 | Ramantamig | Phase 2 / Active, not recruiting | Janssen Research & Development LLC | South Korea, United States, Japan, China, Turkey, Poland, Italy, Israel | Overall Response Rate (ORR) Up to 2 years and 9 months | 2027-06-14 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07210047 is a Phase 1/2, recruiting study with not reported planned participants. Allocation is Non-Randomized, masking is None (Open Label), and the intervention model is Sequential Assignment.
The primary endpoint is “Myeloma responses, including sCR, CR, VGPR, PR, MR, SD, PD, clinical relapse, ORR, CBR, DoR, time to sCR, time to CR, time to VGPR, time to PR, time to MR, as assessed by the investigator according to the IMWG criteria.” over “From enrollment to the end of treatment at 8 months.” The retrieved endpoint description is: Complete Response (CR): Negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, and ≤ 5% plasma cells in the bone marrow. Very Good Partial Response (VGPR): ≥ 90% reduction in serum M-protein plus urine M-protein level \ 25% from lowest response value in M-protein, serum fr.
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of not reported should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
0 recent result records were selected as contextual evidence for Refractory Multiple Myeloma. These records do not establish direct evidence for NCT07210047 unless the registration number matches.
Indexed evidence status
No directly comparable result record was retrieved for this disease query. This is a monitoring gap, not evidence of absence.
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Lenalidomide is indexed as Degradable Molecular Glue with CK1α x CRBN x IKZF1 x IKZF3 biology and a global stage of Approved. The asset profile lists Celgene Corp. as an originator or developer.
Hunilife Biotechnology, Inc. is indexed in an unreported country with the website http://www.hunilife.com. HuniLife Biotechnology is a paramedical research center. The record lists 4 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Lenalidomide is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07210047
Protocol source: https://clinicaltrials.gov/study/NCT07210047
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 15 October 2026.
Lenalidomide in Refractory Multiple Myeloma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Myeloma responses, including sCR, CR, VGPR, PR, MR, SD, PD, clinical relapse, ORR, CBR, DoR, time to sCR, time to CR, time to VGPR, time to PR, time to MR, as assessed by the investigator according to the IMWG criteria. and 2027-11-30 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
